Literature DB >> 592189

Interactions between noradrenaline and 5-hydroxytryptamine involving platelet aggregation [proceedings].

S E Ball, D J Boullin, P A Glenton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 592189

Source DB:  PubMed          Journal:  J Physiol        ISSN： 0022-3751            Impact factor:   5.182


× No keyword cloud information.
  4 in total

1.  A nucleotide with characteristic platelet aggregation and inhibition properties similar to 5-hydroxytryptamine [proceedings].

Authors:  B Oppenheim; M B Youdim
Journal:  Br J Pharmacol       Date:  1979-05       Impact factor: 8.739

2.  Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41,468), a selective 5-HT2-receptor antagonist. 1982.

Authors:  F de Clerck; J L David; P A Janssen
Journal:  Agents Actions       Date:  1994-12

3.  Platelet shape change in patients with psychiatric disorders and treated with phenothiazines, thioxanthines, butyrophenones, benzodiazepines, tricyclic antidepressants and beta-adrenergic blocking agents.

Authors:  D J Boullin
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

4.  Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.

Authors:  F de Clerck; J L David; P A Janssen
Journal:  Agents Actions       Date:  1982-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.